Loading...
XKRX
006280
Market cap1.05bUSD
Dec 05, Last price  
135,400.00KRW
1D
-1.31%
1Q
3.36%
Jan 2017
-13.76%
Name

Green Cross Corp

Chart & Performance

D1W1MN
XKRX:006280 chart
P/E
P/S
0.92
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
4.17%
Revenues
1.68t
+3.27%
442,299,046,000516,096,685,000643,208,349,000791,015,317,000767,911,770,550811,774,313,000888,168,207,110975,327,105,7301,047,812,247,3301,197,903,918,4001,287,916,286,2201,334,877,810,1101,369,709,726,8001,504,115,278,6501,537,825,750,2501,711,312,739,5301,626,643,815,8201,679,891,941,000
Net income
-26.28b
L-1.32%
44,357,145,00048,872,734,00080,524,433,000104,688,642,00055,367,168,00053,643,053,42070,066,278,51083,944,674,44094,967,401,93062,969,546,58053,246,604,74034,429,474,380-11,287,400,06081,048,858,100123,211,805,90065,453,133,850-26,631,783,140-26,280,215,000
CFO
-53.46b
L+876.83%
35,223,947,000-20,729,139,000112,006,156,00084,471,459,00054,855,488,03050,756,715,57029,689,475,48056,763,005,92045,243,777,660-1,742,284,53057,879,006,00014,410,216,14040,291,382,03035,973,500,910125,978,948,880119,154,310,880-5,472,809,765-53,460,079,000
Dividend
Dec 27, 20231500 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Green Cross Corporation, a biopharmaceutical company, develops drugs and vaccines in South Korea. The company provides plasma derivatives, including albumin, immunoglobulin, and antithrombin; and vaccines for hepatitis-B, Hantavirus hemorrhagic fever, influenza, flu, and varicella. It also offers prescription drugs for the bleeding symptom control and hemostasis for persons with hemophilia A; prevention and treatment of bleeding episodes induced by hemophilia A and post-operative treatment; and treatment of neutropenia, hunter syndrome, and liver cancer, as well as treatment of anti-inflammation, pain relief, and osteoarthritis. In addition, the company provides over the counter drugs. It also exports its products to approximately 50 countries. The company has a licensing and collaboration agreement with Tottori University for development of GM1 gangliosidosis chaperone therapy. The company was formerly known as Sudo Microorganism Medical Supplies Company and changed its name to Green Cross Corporation in 1971. Green Cross Corporation was founded in 1967 and is headquartered in Yongin-si, South Korea. Green Cross Corporation is a subsidiary of Green Cross Holdings Corporation.
IPO date
Aug 01, 1989
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT